Study of DCC-3014 in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label Phase 1/2 study of DCC-3014 in patients with malignant
solid tumors and tenosynovial giant cell tumor (TGCT). There will be 2 distinct parts in this
study: Dose Escalation (Phase 1) and Expansion (Phase 2). Phase 1 will enroll both malignant
solid tumor and TGCT patients. Phase 2 will comprise two cohorts (Cohort A and Cohort B) and
will only enroll TGCT patients.